SYNTHESIS AND EVALUATION OF A RADIOIODINATED PHOSPHOLIPID ETHER ANALOG (NM-404) FOR DIAGNOSTIC IMAGING OF PROSTATE CANCER

2000 ◽  
Author(s):  
R. E. COUNSELL ◽  
M. A. LONGINO ◽  
A. N. PINCHUK ◽  
R. W. S. SKINNER ◽  
S. J. FISHER ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging

scholarly journals PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5795
Author(s):  
Constantinos Zamboglou ◽  
Simon K. B. Spohn ◽  
Sonja Adebahr ◽  
Maria Huber ◽  
Simon Kirste ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Dose Escalation ◽  
Treatment Time ◽  
Imaging Techniques ◽  
Phase Iii ◽  
Tumor Control ◽  
Safe Delivery ◽  
Primary Prostate Cancer ◽  
Psma Pet

Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship for patients with primary PCa and especially in patients with high-risk features, as dose escalation leads to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography targeting prostate-specific-membrane antigen (PSMA-PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT/stereotactic body RT, with focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel strategy will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS), and we will assess quality of life in order to detect potential changes.

scholarly journals Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1371 ◽  
Author(s):  
Bogdan Mitran ◽  
Zohreh Varasteh ◽  
Ayman Abouzayed ◽  
Sara S. Rinne ◽  
Emmi Puuvuori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Solid Phase ◽  
Solid Phase Peptide Synthesis ◽  
Binding Specificity ◽  
Tumor Uptake ◽  
Biodistribution Data ◽  
Positron Emission ◽  
Ic50 Values

Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) could improve the diagnostic accuracy in prostate cancer (PCa). The aim of this study was to develop a PSMA/GRPR-targeting bispecific heterodimer for SPECT and positron emission tomography (PET) diagnostic imaging of PCa. The heterodimer NOTA-DUPA-RM26 was produced by manual solid-phase peptide synthesis. NOTA-DUPA-RM26 was labeled with 111In and 68Ga, with yields >98%, and demonstrated a high stability and binding specificity to PSMA and GRPR. IC50 values for natIn-NOTA-DUPA-RM26 were 4 ± 1 nM towards GRPR and 824 ± 230 nM towards PSMA. An in vivo binding specificity 1 h pi of 111In-NOTA-DUPA-RM26 in PC3-PIP-xenografted mice demonstrated partially blockable tumor uptake when co-injected with an excess of PSMA- or GRPR-targeting agents. Simultaneous co-injection of both agents induced pronounced blocking. The biodistribution of 111In-NOTA-DUPA-RM26 and 68Ga-NOTA-DUPA-RM26 revealed fast activity clearance from the blood and normal organs via the kidneys. Tumor uptake exceeded normal organ uptake for both analogs 1 h pi. 68Ga-NOTA-DUPA-RM26 had a significantly lower tumor uptake (8 ± 2%ID/g) compared to 111In-NOTA-DUPA-RM26 (12 ± 2%ID/g) 1 h pi. Tumor-to-organ ratios increased 3 h pi, but decreased 24 h pi, for 111In-NOTA-DUPA-RM26. MicroPET/CT and microSPECT/CT scans confirmed biodistribution data, suggesting that 68Ga-NOTA-DUPA-RM26 and 111In-NOTA-DUPA-RM26 are suitable candidates for the imaging of GRPR and PSMA expression in PCa shortly after administration.

Clinical Staging/Diagnostic Imaging in Salvage Therapy for Prostate Cancer

2020 ◽  
pp. 75-78
Author(s):  
Carla Perna ◽  
Jennifer Uribe ◽  
Santiago Uribe-Lewis ◽  
Stephen E. M. Langley
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Salvage Therapy ◽  
Clinical Staging

Diagnostic Imaging in Low Risk Prostate Cancer: More Harm than Good?

2021 ◽  
Author(s):  
Justin Loloi ◽  
Joshua M. Eccles ◽  
Grant Owens ◽  
Erik Lehman ◽  
Matthew G. Kaag ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Low Risk ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer

scholarly journals Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons

2016 ◽  
Vol 43 (8) ◽  
pp. 1546-1562 ◽  
Author(s):  
Laura Evangelista ◽  
Francesco Bertoldo ◽  
Francesco Boccardo ◽  
Giario Conti ◽  
Ilario Menchi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Bone Metastases ◽  
Response To Therapy ◽  
New Horizons

scholarly journals Multi-stage AI analysis system to support prostate cancer diagnostic imaging

2020 ◽  
Author(s):  
Antony W. Rix ◽  
Jakub Suchánek ◽  
Aman Mehan ◽  
Chris J. L. Doran ◽  
Anwar R. Padhani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Cancer Diagnostic ◽  
Multi Stage ◽  
Analysis System
Sign in / Sign up

Export Citation Format

Share Document